MARKET WIREYahoo Finance • 15h ago
Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare ConferenceYahoo Finance report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
Why PLX Stock slipped -0.77% Today — RQD Quant Desk Flash
$2.59 -0.77% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.58
Protalix BioTherapeutics Inc. (PLX) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $208.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on PLX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is PLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Protalix BioTherapeutics Inc. (NYSE: PLX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $2.59 (-0.77% 1D, market cap $208.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLX ranks #948 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does PLX compare to ARTV and PALI in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PLX carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 48.8%, and ROIC of -13.0%. By comparison, ARTV (Artiva Biotherapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $204.8M) and PALI (Palisade Bio Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $202.2M). Among the 5-stock peer group, PLX leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for PLX?
▼
Per PLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001006281), Protalix BioTherapeutics Inc. generated $52.7M in revenue (-1.2% YoY), -$6.6M in net income, and -$13.6M in free cash flow against $82.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.58 (-0.33%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-15.8% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PLX)Realized 20D OHLCV Swing Band: ±7.8%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY PLX SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+9/20 pts (39% of score)
20D Institutional Volume Accumulation (±7.8% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (35% of score)
FRED Regime × Technicals: 61% of 52W Range • RSI-14 at 47.3 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$2.78-7.9% Next Q
31
Q2 (-2Q)Grade E$2.56-3.1% Next Q
28
Q3 (-1Q)Grade E$2.48+4.4% Next Q
26
CurrentGrade E$2.59-11.1% Hist 90D α
23
Trajectory: E (31) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a PLX Turnaround Squeeze
While PLX currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.65) and Max Pain ($2.72) forces dealer call-delta covering toward $3.35.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $PLX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why PLX Stock slipped -0.77% Today — RQD Quant Desk Flash
Protalix BioTherapeutics Inc. (PLX) slipped -0.77% to $2.59, trading at 61% of its 52-week range ($1.65 – $3.19). Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 61% of its 52-week range ($1.65 – $3.19) with RSI-14 at 47.3 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7.8% around $2.59 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 48.8% gross margin and $0 annual free cash flow.
Live PLX Headlines & Catalysts
MARKET WIRETradingView • 18h ago
Protalix BioTherapeutics, Inc. (DE) Estimates – AMEX:PLXTradingView report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 21h ago
Protalix BioTherapeutics, Inc. (PLX) Seasonal Returns ChartYahoo! Finance Canada report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Complete U.S. Stocks List: Prices, Performance and Key DataTradingKey report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
AC Immune (Nasdaq:ACIU) - Stock AnalysisSimply Wall St report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Guerrilla RF Heads These 3 Top Penny Stocks To WatchYahoo Finance report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring PLX)
- ✓Walkthrough of PLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
PLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +21.60%▲ ASCENDING CHANNEL
2026-11-03O $2.61H $2.61L $2.59C $2.59VOL 249.3K
RES: $2.99SUP: $2.48SMA50: $2.65SMA200: $2.42
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
PLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -1.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on PLX today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for PLX. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PLX)
Health Care Rank #948 of 1016
⚔️ ARTV vs PLX Full Matrix →
1. Head-to-Head Health Care Peer Comparison (PLX vs. ARTV, PALI, IKT, DTIL)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Protalix BioTherapeutics Inc. (PLX) ranks #948 by composite RQD confidence (23/100, grade E) and #568 by equity capitalization ($208.7M). Within this direct 5-issuer industry benchmark cohort, PLX leads on earnings valuation at N/A trailing P/E, while PLX leads on capital efficiency and profitability with -13.0% ROIC and 48.8% gross margin. PALI currently holds the highest overall quantitative score in the immediate peer group at 32/100 (E) compared with PLX at 23/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PLX
ACTIVE
Protalix BioTherapeutics Inc. | E | 23/100 | — | 48.8% | -13.0% | -0.77% | $208.7M | Benchmark Subject |
| ARTV Artiva Biotherapeutics Inc. | E | 27/100 | — | — | -35.0% | -0.95% | $204.8M | /artv-vs-plx → |
| PALI Palisade Bio Inc. | E | 32/100 | — | — | -35.0% | -2.52% | $202.2M | /pali-vs-plx → |
| IKT Inhibikase Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -7.19% | $216.3M | /ikt-vs-plx → |
| DTIL Precision BioSciences Inc. | E | 30/100 | — | — | -35.0% | -5.11% | $194.9M | /dtil-vs-plx → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001006281In its most recent audited fiscal period (FY2025, filed 2025-12-31), Protalix BioTherapeutics Inc. (PLX) reported GAAP revenue of $52.7M (-1.2% vs. FY2024 revenue of $53.4M , and -19.5% cumulative change since FY2023) , GAAP net income of -$6.6M, operating cash flow of -$12.0M, and free cash flow of -$13.6M (-284.4% YoY). On the balance sheet, PLX closed FY2025 with $82.3M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $52.7M | -$6.6M | -$12.0M | -$13.6M | $82.3M | — |
| FY2024 (FY) | 2024-12-31 | $53.4M | $2.9M | $8.7M | $7.4M | $73.4M | — |
| FY2023 (FY) | 2023-12-31 | $65.5M | $8.3M | -$1.3M | -$1.3M | — | — |
3. PLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs PLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Protalix BioTherapeutics Inc. (NYSE: PLX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $2.59 (-0.77% 1D, market cap $208.7M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, PLX ranks #948 in composite RQD confidence.
How does PLX compare to ARTV and PALI in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), PLX carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of 48.8%, and ROIC of -13.0%. By comparison, ARTV (Artiva Biotherapeutics Inc.) holds a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $204.8M) and PALI (Palisade Bio Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $202.2M). Among the 5-stock peer group, PLX leads on earnings multiple (N/A) while PLX leads on capital efficiency (-13.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for PLX?
Per PLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001006281), Protalix BioTherapeutics Inc. generated $52.7M in revenue (-1.2% YoY), -$6.6M in net income, and -$13.6M in free cash flow against $82.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is PLX trading relative to its 50-day, 200-day, and 52-week technical levels?
PLX last traded at $2.59 (-0.77% on volume of 249,290 shares), positioning the stock -2.26% below its 50-day simple moving average ($2.65) and +7.02% above its 200-day simple moving average ($2.42). Across its 52-week range of $1.65 to $3.19, PLX sits at the 61.0% percentile with a 14-day RSI of 47.3 (NEUTRAL RANGE) and an implied next-earnings move of ±7.8% ($2.39 to $2.79).
PLX Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is PLX stock moving today?
Why PLX Stock slipped -0.77% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-13% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 23/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
PLX — Protalix BioTherapeutics Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:40:53Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, PLX scores 28 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The Fundamental Cash Engine pillar scores 1 of 20, reflecting ROIC of -13% and an FCF yield of -6.48%; for a prospective investor, this means the business is not currently generating returns on invested capital or free cash flow that would support the equity value. The Whale 13F Flow pillar scores 12 of 20, indicating institutional accumulation and options positioning that is more constructive than the fundamentals, which is a point of tension an investor should weigh rather than assume. The Insider Conviction pillar scores 3 of 20, reflecting SEC Form 4 and Congressional PTR cluster flow that provides limited support. The Macro Regime Fit pillar scores 10 of 20, with a Beta of 1.0 and sector sensitivity. The Forensic Balance Sheet pillar scores 2 of 20, reflecting an Altman Z-Score of 0.2, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. Taken together, the rating frames PLX as a forensic-risk name where upside would depend on a fundamental turnaround that the current sourced metrics do not yet show.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $52.7M | $-5.5M | $-6.6M | N/A | $-13.6M | $14.7M | N/A |
| FY 2024 | $53.4M | $3.9M | $2.9M | N/A | $7.4M | $19.8M | N/A |
| FY 2023 | $65.5M | $10.5M | $8.3M | N/A | $-1.3M | N/A | N/A |
Per the SEC financials, revenue declined from $65.5M in FY 2023 to $53.4M in FY 2024 and $52.7M in FY 2025, and operating income moved from $10.5M to $3.9M before turning to $-5.5M in FY 2025. Per the market data, gross margin is 48.8%, operating margin -10.4%, and net margin -12.5%, with ROIC at -13%. Per the Roarable RQD rating, the Altman Z-Score is 0.2, the Piotroski F-Score is 2/9, and Debt/Equity is 0.5. Cash is reported at $14.7M for FY 2025 against FCF of $-13.6M.
Open Questions
- What are the company's specific products, indications, and revenue sources, and how do they account for the decline from $65.5M to $52.7M?
- What drove the swing from FY 2024 net income of $2.9M to FY 2025 net loss of $-6.6M, and is the operating loss expected to persist?
- What are the debt obligations, since debt is reported as N/A for every period?
- What institutional or insider holdings sit behind the 12 of 20 Whale 13F Flow pillar score, given the holders section is empty?
- What is the cash runway given FY 2025 FCF of $-13.6M against $14.7M of reported cash?
PLX Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Protalix BioTherapeutics Inc. (PLX) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 15h ago
Protalix BioTherapeutics to Present at the Stifel 2026 Healthcare Conference Yahoo Finance report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 18h ago
Protalix BioTherapeutics, Inc. (DE) Estimates – AMEX:PLX TradingView report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 21h ago
Protalix BioTherapeutics, Inc. (PLX) Seasonal Returns Chart Yahoo! Finance Canada report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Complete U.S. Stocks List: Prices, Performance and Key Data TradingKey report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
AC Immune (Nasdaq:ACIU) - Stock Analysis Simply Wall St report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Guerrilla RF Heads These 3 Top Penny Stocks To Watch Yahoo Finance report covering Protalix BioTherapeutics Inc. (PLX) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
PLX Bull vs. Bear Conversation Board — What's Your Call at $2.59?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PLX 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $2.28 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is PLX (E • RQD 28/100) a Buy at $2.59?
Welcome to the PLX (Protalix BioTherapeutics Inc.) Roar Pit. Current RQD Composite is 28/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.18 (-15.8%)
Spot @ $2.59 Pump the brakes on PLX — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on PLX, but look at what you are paying: current EV/EBITDA multiples with 48.8% gross margins. Unless Protalix BioTherapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
AL AlphaFlow_Cap Verified K Arena Trader 🐂 BULLISH
🎯 Target: $3.08 (+18.9%)
Spot @ $2.59 PLX cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on PLX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.59 (52-wk range $1.65 - $3.19), any beat on forward guidance forces shorts and underweight funds to chase.